gilead has been flat for five years. exclude moderna and biontech, which have, obviously, been in the same stocks the past couple of years, you are not left with anything pfizer, you know, 20 years of, you know, if you look at -- pull up that chart, it hasn't moved in two decades and so you're left with large cap pharma and large-cap biotech by are not leaders at all. the long-term perspeformance, doesn't leave a lot to be desired, especially for portfolio managers that can own anything f they don't like the first layer of this group, the large cap names in the group, it's a low probability that they want to peek under the hood and pick stocks that are smaller >> you mentioned moderna and pfizer i think maybe our viewers might want to dig into this a little bit more obviously, so much attention on the vaccine and what that means for these stocks you think about a moderna where probably the vaccine is a lot more important versus a more diversified play like pfizer, at that point given the relative moves in the stocks and

so any advice from you, josh, would be greatly appreciated on gilead thank you. >> we're going to doter than just chat. we're going to give everybody a crack at this. but josh, you take it first. the question was directed at you. >> yeah. i don't really follow this stock very closely but i would just as a rule of them, a low pe ratio is only indicative of a not very exciting outlook the fact it's underperformed moderna shouldn't be a surprise. there's a possibility the fda could upgrade them from emergency use authorization of remdesivir to a more widespread use of earlier use they are reviewing data now. so maybe that would be an upside catalyst i don't think you're taking a big risk in the stock and there don't appear to be high expectations for the aids franchise here or even the cancer franchise, which is something they just acquired i think there's a lot of potential ways to win here i would stick with it and wait and see if there's something to come >> pete feels your pain. he owns it he's been sticking with it, too, kind of disappointed at the outlook in that. stephanie link,

government funded all the clinical trials to show this drug that gilead had was effective to preventection. there have been many congressional urging of gilead to make this drug freely available since the trials were funded by the u.s. government, and the company probably made a more expensive drug -- promptly made a more expensive drug and marketed that. it is critical to say there was public funding put into this and it was literally paid for by taxpayer dollars and the fact it will not share this with places willing and ready to receive it, not only make up for the untries but for others, is one of -- i just have to say my mind is constantly blown by this degree of injustice. the other thing i want to remind is october 2020 was the type when india and south africa appealed to the wto. they anticipated there could be waves in their country. india has been spared up into that point. a new technology was coming. they said to the wto, ensure that we get a waiver if there is a waiver made on the intellectual property of the life-saving vaccines because there is a waiver that possible i

the fda has only approved one drug to actually treat covid-19 once you get it, remdesivir, made by gilead sciences, based in foster city. a study in "the new england journal of medicine" found remdesivir shortened hospital stays by five days in covid patients and reduced deaths by about 5% compared to a placebo. julia schaletzky: we were looking for things that make remdesivir work better. stephen: at uc berkeley, biochemist julia schaletzky and her staff tested thousands of approved drugs to see if just one would help remdesivir kill the virus. after months of searching, they got a hit. this first slide shows how human cells look in the lab when attacked by sars-covid-2. dr. julia schaletzky: you can see in red where the virus proteins are, and the cells shrivel up and die. stephen: but look at what happens when the scientists treat the cells with a mixture of remdesivir and a hepatitis c drug called velpatasvir. eddie wehri: so it completely eliminates the virus in cells, which is great, but that's just the first step. stephen: so, wait a minute, you're tellin' me, in cells, you're able

she is active on the gilead science board which produces rem does severe the therapy and many doctorsd we are delighted that she is here representing all of the former first ladies of california as an honorary cochair of the nancy reagan centennial commission. as for the governor, after attending a gale on an rotc scholarship, pete wilson served ten years as marie corr infantry officer before he went on to get a law degree from berkeley. a short four years later he was elected to the california assembly, mayor of san diego and then elect for two terms in the united states senate. he definitely missed california as the weather is so much that he came back to be elected governor of california in 1990 and 1994 again. i would like to invite our former governor from the great state of california, pete wilson to the stage. [applause] >> thank you very much john. as john has indicated, i have had a lengthy political career. the nicest part in many respects was the fact that twice i was put into the company of the man for whom this library and foundation are named. and of course is loving and

barack obama back to you >> they were all jumping around after earnings, including am zochblt and gileadt looks like a big beat on remdesivir earnings for the quarter coming in at $2.65. revenue is 7.24 billion dollars versus the average $3 billion estimates. remdesivir came in at $1.9 billion. the company raising its full year forecast across the board especially for the sales now saying it expects to have between 4.5 and 4.8 from its drug talk about its third covid hospitalizations but they expect it back to you. >> i'll come to you. >> exactly i think the biggest thing i was look for is they increased their number they're guiding higher that's something they're going to move up in 2022 i actually was focused on the digital numbers. if you go into a starbucks store, there are higher amounts of digital online orders which may increase efficiencies overtime, but the thing with the same store sales numbers came lower than projections, if you add that as well as higher input and cost, you're going to increase the margins over the past several months. i'm still holding to the smaller positi

," it knows all, forgives all, it is a balm in gilead. ( applause ) meanwhile, big marvel casting newsed the marvel cinematic universe, and will play eros, the god of love and sex. so... harry styles. ( cheers and applause ) meanwhile, "saudi arabia is set to launch an enormous oil-themed 'extreme park'." and to keep the mideast oil theme authentic, the u.s. is going to invade it. ( laughter ) ( applause ) sure, why not. it's your classic family-friendly derelict oilrig-based theme park featuring "three hotels and 11 restaurants spread over a number of connected platforms, as well as roller coaster rides and adrenaline rush activities like bungee jumping and skydiving." just be sure to wear your poncho when you ride the log flume. ( laughter ) meanwhile, it's now been confirmed that "vikings were active at a newfoundland settlement nearly 500 years before christopher columbus crossed the atlantic." this changes everything! now we know that vikings didn't discover america 500 years before columbus didn't! ( laughter ) ( cheers and applause ) >> jon: i like that. >> stephen: hold on, chi

the price target on this one >> it is in the 89 i believe >> okay. 89 overweight for gilead. is three assets in the commercial already available and they have broad platform technology with gene therapy and gene therapy and muscular dystrophy and another dysfunction. they have a base valuation of a f franchise and major swings in shot zone goal for these other gene therapy products over did near term. >> let's get to the juicy one. we have been teasing it all show which of the stocks has a 130% upside >> that's tg therapeutics. 100% upside today, as well. >> let's do tg first. >> yeah. they have a drug that's approved for two end cases in hematology and a drug for multiple s sclerosis next year. the stock was very strong if you look at the chart. pulled back a lot. people thought they were lacking a catalyst this year and then the people confused by the comments on the quarterly call and thought they could sell a billion dollars in 2025 when that's not peak but progress and so the peak is much wider than that and i think there's tremendous disconnect. i think the stock in the

take a pill for a virus than what we have right now, which are either remdesivir, which is where gileadg, or monoclonal antibodies that you have to go and get infused. that is more difficult. the problem is, a fast-moving highly infectious virus, you need to treat people right away. so having a pill that you can take it home that is in every drugstore, eventually, that could make things much, much easier. ultimately, what they are gunning for, think of tamiflu, the influenza drug. they are gunning for something like that. but for covid. merck is likely to be just the first. caroline: the mental image of it being available in any pharmacy, it cost a lot of money. how will they be able to square that circle? robert: it is not clear what the market is going to look like in the long term. that cost is not a commercial cost, that is what the u.s. government is paying for the first initial batch of doses, $1.2 billion in supply, one -- $1.2 billion in the supply deal provided by the u.s. government in one point 7 million courses. how it would look like in the long term as commercial product i

top donors included gilead, $2900 came from the eli lil y ceo, the chair and ceo of bristol-myers.here you have it. it is a very banal and depressing point, but it's true that money almost always wins out in washington. part of this might also be the probleof the fact thabiden split these two bills in part and slow down the momentum of his presidency by trying to get this bipartisan by hi which i think was largely pointless. this has allowed business groups to favor the much smalr bipartisan infrastructure bill opposed to the $3.5 trillion one largely because of the tax increases. perhaps having them together would have neutralized some of that opposition, i don't know. i think because they are split, because my have gone by with nothing happening, it has allowed people like sinema to become a little more brave in their opposition, and at e same time allowed lobbyists and donors to come in and wedge themselves in and pry these two particularly vulnerable democratic senatorspart from the rest of the caucus. it is an unfortunate situation. amy: speaking about this issue of the person

gilead sciences and biogen and amgen.ee of the worst performing stocks within the nasdaq 100 perhaps, carl, perhaps, deeddei a move as people take stock in what is happening in biotech. >> we talked about this yesterday, some of the pandemic darlings losing a little momentum another stock i want to identify that just opened this week for trade and that is rent the runway it has now closed lower every day since that wednesday ipo it opened at $23 priced above at the high end of its range. but, look, now, it's trading below $19 a share. take a lookt a ipos more broadly. substantially underperforming the market here's the renaissance ipo index versus the triple q. cramer tweeted two, and then there's everything else. he'd stick with everything else. >> yeah, i wonder how to put that up against this really, i think, weird action in zendesk and what that says about risk and what that says overall investor appetite as we see some of the most successful companies in the market. apple, amazon dealing with supply chain crunch issu

had other things too, but gilead did very well in developing tamiflu but there was a time long beforeing could come and be a big deal and people said you should have some tamiflu. it's for each person >> it's a big deal, it's very difficult to get it and figure it out, get access to it within two days >> or if you have it >> if you have it. within two days, you have to have the symptoms, get to the doctor, get a flu test have that doctor then prescribe it to you. all of that happens in the first two days of feeling symptoms most people aren't quick enough to make that move. you can get a covid test today if you are having symptoms you would know immediately and easy within five days be able to be on this >> sometimes it's good to have a doctor in the family >> i was going to say that >> he wasn't in my family. that itself so weird >> he was you didn't know it >> in 2005 >> following two other big stories as we begin this hour. the drama in the markets and the drama in washington. dom chu is here to talk about the former ylan mui, dom, we'll start with you joe, first of all, the tamifl

and one of the top holdings, gilead seeing strong demand for r remdesivir but says other drugs 'rn'ts of polygons here! what's going on? where's regina? hi, i'm ladonna. i invest in invesco qqq, a fund that gives me access to the nasdaq-100 innovations, like real time cgi. okay... yeah... oh. don't worry i got it! become an agent of innovation with invesco qqq >>> welcome back i'm rahel solomon. president biden and the first lady, met with pope francis at the vatican today. meeting lasted about 45 minutes, according to the vatican and followed by the united nations climate summit in scotland early next week >>> u.s. traffic deaths soaring 18.4% in the first half of 2021. according to a department of transportation report that estimates 20,000 died in motor vehicle crashes from january to june the deadliest on american roads since 2006 >>> and a high tide leading to flooding on roadways the delaware river over flowing and spilling on to roads a strong storm is expected to hit the area tonight forecasters say heavy rains could cause the river to overflow again between now and then coul

it sound like something straight out of gilead congresswoman barra lee and michelle kelan organizers of the freedom rally. i want to thank you. i heard you say your mother told you this is your business. since the government made it their business, i think the testimony is quite powerful. what's your message to women today living if states that are trying to basically snatch their rights to abortion away and having to go to black alley abortion clinics. >> thank you for having me, these decision, first of all are gut wrenching, you heard corey and camilla and myself. these are traumatic decisions. it's one's personal decision period, dot, dot, even talking about it, it's very difficult i know this is a personal matter. it's no one's business. i was compelled to speak out. what is going to happen is we will go back to illegal abortions, people will die as a result because they're going to be the black and brown people who don't have the money low income people to travel to other states. these marches, rallies and what is taking place throughout the country is so important it's importa

a society does against women looks like and sadly, listen, we are not too far away from becoming gileadeir jobs. they're dropping out of the workforce by the hundreds of thousands and men are gaining rights as they wrench away a woman's right to abortion. so it's no wonder that status women's treatment in society is at an all-time low even though men are okay with that. joining me to talk about it is dr. christina greer from fordham university. also author of the black ethnics and another christina. beltran. an associate professor at nyu and author of cruelty as citizenship. ladies, very happy to have you with me. christina beltran, i'll start with you. you know, i look at what's happening in society and when you break down this data, women of color who were democrats are mostly dissatisfied yet white republican women were fine with the status quo, which i find interesting because white republican women will also have an adverse impact by some of these policies that will impact their life in a negative way as well. why do you think that divide exists? >> well, i think it's really tellin

withdrawal of our airpower which was the afghan forces differential advantage for theh taliban's different gileadage was the isi and other groups and it was there in scrupulousness and they are willing to terrorize. that's their differential of vantage so i don't think it's a mystery at all and they think it is -- it should be unacceptable i think to disparage the afghans and over 60,000 of them made the ultimate sacrifice and have those freedoms taken away. >> thank you sir. the dome of time has expired and i now work them -- recognize mr. -- i agree with the witnesses perspectives. i think you all present the complexity of building a successful government there and the like. given afghanistan -- of my subcommittee i'd like to focus my time on the current situation that we have and how we ought to think about approaching this and maybe ill start with ambassador crocker. i've had the right conversation saying while our relationship was at an all-time low this is a point in time where they have a step up like a government that's forming in afghanistan and going in the direction they would like in